This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tianyin Pharmaceutical's CEO Discusses FQ3 2011 Results - Earnings Call Transcript

Any statements set forth in this presentation, that are not historical facts or forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include but are not limited to such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, fluctuation in the economy, results of research and development, failure to obtain regulatory approvals and other information detailed from time to time in TPI’s filing and future filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this presentation are made only for this date and TPI’s under no obligation to revise or update these forward-looking statements.

FQ3 2011 ending March 31 st 2011 financial highlights – Revenue increased 56.3% year over year to $24.9 million from $15.9 million the year earlier.

Operating income increased 39.9% year over year to $5 million from $3.6 million a year earlier.

Net Income increased 27.7% to $3.7 million year over year from $2.9 million a year earlier.

Earnings per share of $.13 per basic share, or $.12 per diluted share, up from $.11 per basic share or $.09 per diluted share a year earlier. A gain of 19.3% and 35.5% respectively.

Cash and cash equivalents totaled $31.1 million on March 31 st 2011 or $1.10 per basic share in cash.

Sales for the quarter ended March 31 st 2011 was $24.9 million, up 56.3% as compared to $15.9 million for the quarter ended March 31 st 2010.

Although our generic pharmaceutical sales have been under pricing pressure at the beginning of this third quarter, the channel expansion, optimized production facility usage, and the continuous stream of Tianyin Medicine Trading, TMT, distribution revenue supported the quarterly sales growth. With the current hospital coverage at 880 hospitals up from 850 hospitals from the beginning of fiscal year 2011, we are targeting to reach 900 hospitals by the end of fiscal year 2011 ending June 30 th 2011.

Revenues from the top selling products are Gingko Mihuan Oral Liquid, GMOL, $5.6 million. Apu Shuangxin Benorylate Granules, APU, $1.8 million. Azithromycin Tablets, AZI, $.98 million. Xuellian Chongcao Oral Liquid, XLCC, $1.1 million. Qing Re Jie Du Oral Liquid, $.77 million. These products totaled $10.2 million in sales, representing 41.2% of the quarterly revenue.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.49 -10.32 -0.50%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs